Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 510-523

  Liu, Xuesong ^a   Shi, Yan ^a   Maag, David X ^a   Palma, Joann P ^a   Patterson, Melanie J ^a   Ellis, Paul A ^a   Surber, Bruce W ^a   Ready, Damien B ^a   Soni, Niru B ^a   Ladror, Uri S ^a   Xu, Allison J ^a   Iyer, Ramesh ^a   Harlan, John E ^a   Solomon, Larry R ^a   Donawho, Cherrie K ^a   Penning, Thomas D ^a   Johnson, Eric F ^a   Shoemaker, Alexander R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROSO DERIVATIVE; TEMOZOLOMIDE; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG STRUCTURE; ENZYMATIC ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BENZIMIDAZOLES; BRCA2 PROTEIN; CELL LINE, TUMOR; CYSTEINE; DACARBAZINE; DNA REPAIR; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS, EXPERIMENTAL; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862907868     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1973     Document Type: Article

References (47)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. PolyADP-ribose: novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28. (Pubitemid 44036457)
2. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93. (Pubitemid 39128102)
3. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204. (Pubitemid 351301852)
4. Amé JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADPribose) polymerase. J Biol Chem 1999;274:17860-8.
5. Kawamitsu H, Hoshino H, Okada H, Miwa M, Momoi H, Sugimura T. Monoclonal antibodies to poly(adenosine diphosphate ribose) recognize different structures. Biochemistry 1984;23:3771-7.
6. Penning TD. Small-molecule PARP modulators - current status and future therapeutic potential. Curr Opin Drug Discov Devel 2010;13: 577-86.
7. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, et al. Inhibition of polyADP-ribose polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009;15:1241-9.
8. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active polyADP-ribose polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37. (Pubitemid 46795129)
9. Rottenberg S, Jaspers JE, Kersbergen A, Van der Burg E, Nygren AOH, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
10. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-3S-piperidin-3-ylphenyl}-2H-indazole-7- carboxamide MK-4827: a novel oral polyADP-ribose polymerase PARP inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009;52:7170-85.
11. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. Potentiation of temozolomide cytotoxicity by polyADPribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008;6:1621-9.
12. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the polyADP-ribose polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23.
13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly ADP-ribose polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
15. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral polyADP-ribose polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of- concept trial. Lancet 2010;376:235-44.
16. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral polyADP-ribose polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of- concept trial. Lancet 2010;376: 245-51.
17. Mendeleyev J, Kirsten E, Hakam A, Buki KG, Kun E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide: metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995;50:705-14.
18. Kun E, Mendeleyev J, Hakam A, Kirsten E. Enzymatic mechanism of the tumoricidal action of 4-iodo-3- nitrobenzamide. Mol Med Report 2009;2:739-42.
19. Ossovskaya V, Li L, Broude EV, Lim C-U, Roninson I, Bradley C, et al. BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5552.
20. Ossovskaya V, Li L, Bradley C, Sherman B. Activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr 2311.
21. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
22. O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29 (suppl; abstr 1007).
23. Langelier M, Servent KM, Rogers E, Pascal JM. A third zinc-binding domain of human polyADP-ribose polymerase-1 coordinates DNA-dependent enzyme activation. J Biol Chem 2008;283:4105-14.
24. Langelier M, Planck JL, Roy S, Pascal JM. Crystal structures of polyADP-ribose polymerase-1 PARP-1 zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 2011;286:10690-701.
25. Huth JR, Mendoza R, Olejniczak ET, Johnson RW, Cothron DA, Liu Y, et al. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 2005;127:217-24. (Pubitemid 40094385)
26. Hesk D, Das PR, Evans B. Deuteration of acetanilides and other substituted aromatics using {Ir(COD)(Cy3P)(Py)]PF6 as catalyst. J Lab Comp Radiopharm 1995;36:497-502.
27. Filipovic DM, Meng X, Reeves WB. Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells. Am J Physiol 1999;277:428-36.
28. Elstrodt F, Hollestelle A, Nagel JHA, Gorin M, Wasielewski M, van d OA, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-5. (Pubitemid 43166006)
29. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of polyADP-ribose polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011;103:334-46.
30. Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008;68:5023-30.
31. Palma JP, Wang Y-C, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009;15:7277-90.
32. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009;7: 1686-92.
33. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly ADP-ribose polymerase: an issue of potency. Cancer Biol Ther 2005;4:934-6. (Pubitemid 41598586)
34. Tentori L, Leonetti C, Scarsella M, Giulia DA, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9. (Pubitemid 37413592)
35. Palma JP, Rodriguez LE, Bontcheva D, Velitchka D, Bouska JJ, Bukofzer G, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28:2625-35.
36. Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, et al. An enzyme-linked immunosorbent polyADP-ribose polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem 2008;381:240-7.
37. LoRusso P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29 (suppl; abstr 3000).
38. Kummar S, Chen A, Ji J, Allen D, Egorin M, Gandara D, et al. A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. J Clin Oncol 2010;28:15s (suppl; abstr 2605).
39. Fong PC, Boss DS, Yap TA, Tutt AN, Wu P, Mergui RM, et al. Inhibition of polyADP-ribose polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
40. Schelman WR, Sandhu SK, Moreno GV, Wilding G, Sun L, Toniatti C, et al. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). J Clin Oncol 2011;29 (suppl; abstr 3102).
41. Isakoff S, Overmoyer B, Tung N, Gelman R, Giranda V, Bernhard K, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010;28:15s (suppl; abstr 1019).
42. Carey LA, Sharpless NE. PARP and cancer - if it's broke, don't fix it. N Engl J Med 2011;364:277-9.
43. Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7.
44. Ji J, Lee MP, Kadota M, Zhang Y, Parchment RE, Tomaszewski JE, et al. Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2011. Abstract nr 4527.
45. Maegley KA, Bingham P, Dalvie D, Bergqvist S, Tatlock J, Kania R. An in vitro mechanistic comparison of clinical PARP inhibitors. PARP 2010. In: Proceedings of the 18th International Conference on ADPribose metabolism; 2010 Aug 18-21; Zurich, Switzerland. Abstract nr 72.
46. Seth D, Stamler JS. The SNO-proteome: causation and classifications. Curr Opin Chem Biol 2011;15:129-36.
47. Yu Z, Kuncewicz T, Dubinsky WP, Kone BC. Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitricoxide synthase gene. J Biol Chem 2006;281:9101-9. (Pubitemid 43864623)